Diverse levels of immunogenicity can be seen in human recombinant proteins, humanized antibodies, and diverse therapeutic proteins. There is a chance of triggering an immunological response in clinical applications. The body generates a harmful immune response that leads to the action of drug-resistant antibodies. Every biotherapeutic agent has to have resistant antibodies identified at some point during the course of their drug development process.
Our company provides customers with professional antibody immunogenicity analysis and clearance services that can be customized for their innovative scientific research. We will evaluate each project individually before providing analytical recommendations and fees.
Service Overview
Our company has techniques for determining how immunogenic recombinant proteins are as well as some solutions to lessen their immunogenicity. Our investigation of immunogenicity is performed in layers, beginning with sample screening, followed by confirmation, and concluding with semi-quantitative characterization (titration). It could be necessary to add more characterization, like domain specificity.
For a range of biotherapeutic agents, such as monoclonal antibodies, enzymes, and fusion proteins, we have created immunogenicity assays. We are adept at using acid digestion techniques to find antibodies when there are too many biotherapeutic drugs present.
Services Contents
- Find the immunogenic sites of proteins by analyzing the binding sites of proteins and HLA class II molecules, and mutate amino acids at the immunogenic sites to reduce or remove protein immunogenicity.
- Verify the immunogenicity of mutated antibodies by CD41 T cell proliferation assay.
Our company has a wide variety of platforms to choose from, which helps us to select the best platform for your immunogenicity assay needs. We have a proven track record of developing and validating drug-resistant antibody assays to support clinical and non-clinical studies.
Research Capabilities
Neutralizing antibody (nAb) assay specificity
Depending on the mechanism of action or method of known standard drug classes, we can assist you in developing, validating, and implementing strategies for immunogenicity assays to detect neutralizing activity, ranging from cell-based bioassays to competitive ligand binding assay (LBA) formats to enzymatic assays.
If you are looking for smarter, higher quality solutions that incorporate best practices, please feel free to contact us.
Related Services
It should be noted that our service is only used for research, not for clinical use.
